CSL Behring News
CSL Behring News
First SCIg Approved for CIDP
HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP
World Haemophilia Day
CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to t…
Patient Enrolled in CSL112 Clinical Trial
The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medi…
Making Forbes’ Top Global Employers List
Global biotech leader rated at no. 42 for patient focus, innovation and sustainable g…
New National Fractionation Agreement
CSL Behring today announced that it has signed an agreement with the National Blood A…